Bright Minds Biosciences
DRUG
6 hedge funds and large institutions have $309K invested in Bright Minds Biosciences in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 5 closing their positions.
4.93% more ownership
Funds ownership: 0.66% → 5.59% (+4.9%)
5% less capital invested
Capital invested by funds: $326K → $309K (-$17.1K)
25% less funds holding
Funds holding: 8 → 6 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$173K |
| 2 |
HF
HRT Financial
New York
|
+$35.6K |
| 3 |
VF
Virtu Financial
New York
|
+$34.9K |
| 4 |
APC
Aspire Private Capital
Cornelius,
North Carolina
|
+$267 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$9.53K |
| 2 |
CCA
Checchi Capital Advisers
Beverly Hills,
California
|
-$8.06K |
| 3 |
BlackRock
New York
|
-$6.29K |
| 4 |
Renaissance Technologies
New York
|
-$6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AI
1
AdvisorShares Investments
Bethesda,
Maryland
| $267K | +$173K | +64,867 | +63% |
|
|
VF
2
Virtu Financial
New York
| $21K | +$34.9K | +13,104 | New |
|
|
HF
3
HRT Financial
New York
| $21K | +$35.6K | +13,370 | New |
|
|
APC
4
Aspire Private Capital
Cornelius,
North Carolina
| $160 | +$267 | +100 | New |
|
|
5
BlackRock
New York
| $2 | -$6.29K | -2,359 | -100% |
|
|
TSS
6
Two Sigma Securities
New York
| – | -$9.53K | -3,345 | Closed |
|
|
CCA
7
Checchi Capital Advisers
Beverly Hills,
California
| – | -$8.06K | -2,828 | Closed |
|
|
8
Renaissance Technologies
New York
| – | -$6K | -2,240 | Closed |
|
|
9
UBS Group
Zurich,
Switzerland
| – | -$1.2K | -420 | Closed |
|
10
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1.03K | -387 | -80% |
|
DRUG Hedge Fund Activity: Q3 2023 in Review
6 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Bright Minds Biosciences (DRUG) for Q3 2023, worth a combined $309K — down 5.2% from $326K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of DRUG and 3 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was AdvisorShares Investments, adding an estimated $173K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $9.53K sold.
- 6 institutional investors held Bright Minds Biosciences (DRUG) as of Q3 2023, down from 8 in Q2 2023.
- Funds reported $309K of Bright Minds Biosciences stock for Q3 2023, down 5.2% quarter-over-quarter.
- 3 funds opened new Bright Minds Biosciences positions in Q3 2023 and 5 closed out, a net change of -2 holders.
- The largest Bright Minds Biosciences buyer in Q3 2023 was AdvisorShares Investments, an estimated $173K added.
- The largest Bright Minds Biosciences seller in Q3 2023 was Two Sigma Securities, an estimated $9.53K sold.
Based on aggregated 13F filings for Q3 2023.